Last updated: April 24, 2026
Who Supplies Edoxaban Tosylate?
Edoxaban tosylate is the tosylate salt of edoxaban (a direct factor Xa inhibitor). The patent and commercial supply landscape is typically split into: (i) API manufacturers for edoxaban or edoxaban tosylate and (ii) salt-form and crystallization/solid-state service providers that produce the marketed salt form under commercial or toll arrangements.
Important: The information needed to produce a complete, accurate supplier roster (company names tied to edoxaban tosylate specifically, not “edoxaban”) must be sourced from reliable commercial and regulatory databases (e.g., DMFs, WHO/EMA/FDA lists, or supplier technical catalogs). Without those source-backed entries, listing suppliers would risk mixing firms that supply edoxaban base with those that supply the tosylate salt, which are not interchangeable for compliance and process control.
Current Supplier Mapping (API vs. Salt-Form Responsibility)
| Supply role |
What the supplier provides |
What to verify for edoxaban tosylate |
| API manufacturer |
Edoxaban API and sometimes salt form |
DMF/letter entries and whether the registered form is the tosylate salt |
| Salt-form / solid-state provider |
Crystallization, polymorph control, and conversion to specific salt |
Evidence that the exact edoxaban tosylate form is produced and qualified for the intended market |
| Toll manufacturer (integrated) |
Conversion, drying, milling, blending, packaging under QC |
Certificates that specify edoxaban tosylate identity and specs, not “edoxaban” broadly |
What a compliant supplier shortlist must contain
A usable supplier list for edoxaban tosylate should include, at minimum, the following proof points per supplier:
- Registered product form: “edoxaban tosylate” (not edoxaban base) in the relevant regulatory filing or technical dossier
- Solid-state control: salt form confirmation and impurity profile aligned to the supplier’s release specs
- Scale capability: commercial batch capability (pilot to GMP scale)
- Documentation: DMF reference (if applicable), COA sample format, and analytical methods for identity and assay
Key Takeaways
- Supplier identification for edoxaban tosylate must be sourced to show the firm supplies the tosylate salt, not only edoxaban base.
- The market splits between API producers and salt/solid-state providers; compliance depends on the exact form in regulatory and QC documentation.
- A valid shortlist is built from DMF/filing-form evidence, solid-state qualification, and release specs that explicitly reference edoxaban tosylate.
FAQs
1) Is “edoxaban” the same as “edoxaban tosylate” for procurement?
No. The marketed API form matters for regulatory registration, purification/impurity profile, and solid-state performance. Procurement should require edoxaban tosylate specifications and identity testing aligned to that salt.
2) Who typically supplies edoxaban tosylate: API manufacturers or salt-form specialists?
Both. Many API firms can supply salt forms, while some suppliers specialize in salt formation and crystallization under toll or custom manufacture arrangements, provided they qualify the exact salt form.
3) What filings or records should a supplier’s listing be based on?
Supplier qualification typically relies on regulatory submissions (for example, DMF-linked API disclosures) and product documentation that explicitly names edoxaban tosylate as the supplied form.
4) What QC evidence should be required for edoxaban tosylate?
At minimum: identity confirmation for the tosylate salt, assay, water and residual solvent controls, impurity limits, and a validated method set that supports the specific salt form.
5) Can a supplier switch between edoxaban base and edoxaban tosylate without a change notification?
Not in regulated workflows. Salt changes affect physical properties and can alter impurity profiles, so the manufacturing and regulatory history must match the final salt form used for the product.
References (APA)
[1] International Council for Harmonisation (ICH). (2009). ICH guideline Q7: Good manufacturing practice for active pharmaceutical ingredients. ICH.
[2] FDA. (2024). Drug Master File (DMF) program. U.S. Food and Drug Administration.
[3] EMA. (2023). Guidance on the submission of data for variations and lifecycle management of products. European Medicines Agency.
